Amgen’s Prolia Bone Drug Is Poised For Clearance In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Two out of three indications ain’t bad: Panel votes for use in post-menopausal osteoporosis and bone loss in prostate cancer.